The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women

Health Technology Assessment

Volumn 11, Issue 4, 2007, Pages 1-80

  Stevenson, M ^a   Davis, S ^a   Lloyd Jones, M ^a   Beverley, C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; FLUINDOSTATIN; PARATHYROID HORMONE[1-34]; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RALOXIFENE; STRONTIUM RANELATE; TETRACYCLINE; VITAMIN D;

ABDOMINAL PAIN; ALGORITHM; AMNESIA; BONE DENSITY; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COHORT ANALYSIS; CONSCIOUSNESS; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA ANALYSIS; DATA BASE; DERMATITIS; DIAGNOSTIC ACCURACY; DIARRHEA; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; ECZEMA; EVIDENCE BASED MEDICINE; FEMALE; FEMUR FRACTURE; FOOD; FOOD DRUG INTERACTION; FRAGILITY FRACTURE; GASTRITIS; GASTROINTESTINAL TOXICITY; HIP FRACTURE; HUMAN; INFORMATION RETRIEVAL; INTESTINE INFARCTION; LOOSE FECES; LUNG EMBOLISM; MATHEMATICAL COMPUTING; MEDICAL INFORMATION; MEDICAL LITERATURE; MENTAL DISEASE; META ANALYSIS; MILK; MORTALITY; NAUSEA; NEUROTOXICITY; OSTEOPENIA; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SEIZURE; SENSITIVITY ANALYSIS; SIDE EFFECT; SKIN ALLERGY; SYSTEMATIC REVIEW; TREATMENT DURATION; ULCER; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; WORLD HEALTH ORGANIZATION;

EID: 33947164810     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11040     Document Type: Review

References (102)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 2003;94:646-50.
2. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International variations in hip fracture probabilities: implications for risk assessment. J Bone Mine Res 2002;17:1237-44.
3. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Study of Osteoporotic Fractures Research Group. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med 1999;159;1215-20.
4. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. BMJ 1993;307:1248-50.
5. Torgerson DJ, Dolan P. The cost of treating osteoporotic fractures in the United Kingdom female population - the author replies. Osteoporos Int 2000;11:551-2.
6. Burge RT, Worley D, Johansen A, Bhattacharyya S, Bose U. The cost of osteoporotic fractures in the UK: projections for 2000-2020. Journal of Medical Economics 2001;4:51-52.
7. World Health Organization. Assessment of fracture risk and its application to screening for postmenopousal osteoporosis. Report No. 843. Geneva: WHO; 1994.
8. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
9. Kanis JA, Gluer CC. Committee of Scientific Advisors, International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporosis Int 2000;11:192-202.
10. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-9.
11. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 2005;20(7):1185-94.
12. Holt G, Khaw KT, Reid DM, Compston JE, Bhalla A, Woolf AD, et al. Prevalence of osteoporotic bone mineral density at the hip in Britain differs substantially from the US over 50 years of age: implications for clinical densitometry. Br J Radiol 2002;75:736-42.
13. Office for National Statistics. National population projections 1998-based. Series PP2, No 22. 2000. London: The Stationery Office.
14. Merck Sharp & Dohme. The clinical and cost effectiveness of alendronate (Fosamax®) for the treatment of osteoporosis and prevention of fractures. Report for submission to the National Institute for Clinical Excellence; 29 November 2002.
15. Eli Lilly and Company. The clinical effectiveness and cost effectiveness of Forsteo (teriparatide) in the treatment of osteoporosis. Submission to the National Institute for Clinical Excellence; 29 November 2002.
16. Eli Lilly and Company. The clinical effectiveness and cost effectiveness of Evista (raloxifene) in the prevention and treatment of osteoporosis. Submission to the National Institute for Clinical Excellence; 29 November 2002.
17. Procter and Gamble Pharmaceuticals. The clinical and cost-effectiveness of Didronel PMO in the prevention of osteoporotic fractures. Submission to the National Institute for Clinical Excellence; 2002.
18. Alliance for Better Bone Health: Aventis UK and Procter & Gamble Pharmaceuticals UK. The clinical and cost effectiveness of risedonate in the prevention of osteoporotic fracture. Submission to the National Institute for Clinical Excellence; 2 December 2002.
19. Servier Laboratories. Strontium ranelate for the prevention of postmenopausal osteoporotic fractures. Submission to the National Institute for Clinical Excellence; 2005.
20. Johnell O, Kanis JA, Jonnson B, Oden A, Johansson H, De Laet C. The burden of hospitalised fractures in Sweden. Osteoporos Int 2005;16:222-8.
21. Singer BR, McLauchlan GJ, Robinson CM, Christie J. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J.Bone Joint Surg Br 1998;80:243-8.
22. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 2000;11:669-74.
23. Stevenson M, Lloyd Jones M, de Nigris E, Brewer N, Oakley J. The clinical effectiveness and cost effectiveness of prevention and treatment of osteoporosis. URL: http://www.nice.org.uk/pdf/ Assessment_reportøteo.pdf 2005;1-408. Accessed 3 May 2005.
24. Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001;12:417-27.
25. O'Hagan A. Curve fitting and optimal design for prediction (with discussion).Journal of the Royal Statistical Society Series B 1978;40(1):1-42.
26. Stevenson MD, Oakley J, Chilcott JB. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Dec Making 2004;24:89-100.
27. Stevenson M. The clinical and cost effectiveness of prevention and treatment of osteoporosis. Addendum to assessment report 2005;1-13. URL: http://www.nice.org.uk/pdf/ Addendum_AR∀r_consultation_03_10_03.pdf. Accessed 3 May 2005.
28. Stevenson M. The clinical and cost effectiveness of prevention and treatment of osteoporosis. Second addendum to assessment report. 2005; 1-9. URL: http://www.nice.org.uk/pdf/secondosteoaddendum.pdf. Accessed 3 May 2005.
29. Johansen A, Evans RJ, Stone MD, Richmond PW, Lo SV, Woodhouse KW. Fracture incidence in England and Wales: a study based on the population of Cardiff. Injury 1997;28:655-60.
30. Klotzbeucher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39.
31. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, and Kanis JA. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998;8:599-603.
32. Meyer HE, Tverdal A, Falch JA, Pedersen JI. Factors associated with mortality after hip fracture. Osteoporos Int 2000;11:228-32.
33. Poor G, Atkinson EJ, O'Fallon WM, Melton III. Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res 1995;319:260-5.
34. Todd CJ, Freeman C, Camilleri-Ferrante C. Anglian audit of hip fracture 2. Cambridge: Cambridge Health Services Research Group; 1999.
35. Parker MJ, Anand JK. What is the true mortality of hip fractures? Public Health 1991;105:443-6.
36. Center JR, Nguyen TV, Schneider D, Sambrook PN, and Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82.
37. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 2003;18:1254-60.
38. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61.
39. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004;15:108-12.
40. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:38-42.
41. Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G. Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol 1996;25:30-8.
42. Government Actuary Department. Expectation of life: United Kingdom females. London: GAD; 1999.
43. Browner WS, Seeley DG, Vogt TM, Cummings SR. Study of Osteoporotic Fractures Research Group. Non-trauma mortality in elderly women with low bone mineral density. Lancet 1991;338:355-8.
44. Johansson C, Black D, Johnell O, Oden A, Mellstrom D. Bone mineral density is a predictor of survival. Calcif Tissue Int 1998;63:190-6.
45. Van Der Klift M, Pols HA, Geleijnse JM, Van Der Kuip DA, Hofman A, De Laet CE. Bone mineral density and mortality in elderly men and women: the Rotterdam Study. Bone 2002;30:643-8.
46. EMEA. Scientific discussion. 2004. European Medicines Agency. http://www.emea.eu.int/humandocs/Humans/EPAR/protelos/protelos.htm. Accessed 4 April 2005.
47. Topol A. Strontium ranelate. APC/DTC Briefing Document. London New Drugs Group; 22 December 2004.
48. EMEA. Summary of product characteristics. Annex I. 2004.
49. Joint Formulary Committee. British National Formulary 49. 2005. British Medical Association and Royal Pharmaceutical Society of Great Britain. http://www.bnf.org/bnf/. Accessed 10 April 2005.
50. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al., for the FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-24.
51. Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
52. Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart 2002;88:203-6.
53. Insull W, Troendle A, Silvers A, Dunne CW. Substantial non-compliance to dose and time prescriptions for medications treating hypercholesterolaemia. Atherosclerosis 1995;115:S93.
54. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
55. Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M, et al. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002;109:874-85.
56. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
57. Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-6.
58. Gillespie WJ, Avenell A, Henry DA., O'Connell DL, Robertson J. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis (Cochrane Review). In Cochrone Library (Issue 4). Oxford: Update Software; 2001.
59. Prendiville W, Elbourne D, Chalmers I. The effects of routine oxytocic administration in the management of the third stage of labour: an overview of the evidence from controlled trials. BJOG 1988;95:3-16.
60. Berlin JA. Does blinding of readers affect the results of meta-analyses? Lancet 1997;350:185-6.
61. Clark HD, Wells GA, Huet C, McAlister FA, Salmi LR, Fergusson D, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 1999;20:448-52.
62. Seeman E, Vellas B, Roux C, Adami S, Aquino J, Semler J, et al. First demonstration of the efficacy of an anti-osteoporotic treatment in very elderly osteoporotic women. American Society of Bone and Mineral Research 26th Annual Meeting 2004; Presentation no. 1219. http://www.asbmr.org/meeting/abstract.cfm. Accessed 1 April 2005.
63. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-6.
64. Meunier PJ, Roux C, Seeman E, Sergio O, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
65. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 2005;90:2816-22.
66. Meunier PJ, Reginster JY. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int 2003;14:S66-76.
67. Reginster JY, Spector T, Badurski J, Ortolani S, Martin TJ, Diez-Perez A, et al. A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate phase 3 program. Osteoporos Int 2002;13:S30.
68. Servier Laboratories. Strontium ranelate for the prevention of postmenopausal osteoporotic fractures. Submission to the National Institute for Health and Clinical Excellence; 2005.
69. Reginster JY, Sawicki A, Devogelaer JP, Padrino JM, Brandi MI, Fardellone P, et al. Rapid and sustained anti-fracture efficacy of strontium ranelate in postmenopausal osteoporosis. Arthritis Rheum 2002;46:S584-5.
70. Reginster JY, Balogh A, Badurski J, Spector TD, Pors-Nielsen S, Felsenberg D, et al. Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent vertebral fracture. Osteoporos Int 2003;14:S7-8.
71. Sawicki A, Reginster JY, Roux C, Rubinacci A, Diaz-Curiel M, Kaufman J, et al. Strontium ranelate reduces the risk of vertebral fractures in postmenopausal women with osteopenia. Osteoporos Int 2004;15:S119-20.
72. Seeman E, Devogelaer JP, Lorenc RS, Spector R, Brixen K, Vellas B, et al. Strontium ranelate: the first anti-osteoporotic agent to reduce the risk of vertebral fracture in patients with lumbar osteopenia. Osteoporos Int 2004;15:507-8.
73. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87.
74. Kayser J, Ettinger B, Pressman A. Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 2001;8:328-32.
75. Ettinger B, Pressman A, Schein J, Silver P, Chan J, Connolly N. Survey of women taking alendronate: prevalence of non-compliance with instructions and discontinuation. Osteoporos Int 1997;7:46.
76. Society for Endocrinology. Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis. Submission to the National Institute for Health and Clinical Excellence; 2005.
77. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51.
78. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 2002. URL: http://www.bnf.org/
79. Stevenson MD, Lloyd Jones M, Davis S, Beverley C. The clinical effectiveness and cost effectiveness of technologies for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Assessment Report prepared for the National Institute for Health and Clinical Excellence by University of Sheffield, School of Health and Related Research; 2005. pp. 1-104.
80. Drummond MF, Jefferson TO. BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
81. Stevenson M, Lloyd Jones M, de Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9(22):1-160.
82. Stevenson MD, Brazier JE, Calvert NW, Lloyd-Jones M, Oakley J, Kanis JA. Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. Journal of the Operational Research Society 2005;56(2):214-21.
83. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
84. Sox HC, Blatt MA, Higgins MC, Marton KI. Medical decision making. Boston, MA: Butterworth-Heinemann; 1998.
85. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
86. National Institute for Clinical Excellence. 2003. URL: http://www.nice.org.uk/nice-web/. Accessed 22 April 2005.
87. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-21.
88. National Institute for Clinical Excellence. URL: http://www.nice.org.uk/ pdf/TAP_Methods.pdf. Accessed 22 April 2005.
89. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004;15:20-6.
90. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd-Jones M. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002;6(29).
91. Curtis L, Netten A. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2004.
92. National Institute for Clinical Excellence URL: http://www.nice.org.uk/ pdf/Alz_assessment_report_0205.pdf. Accessed 22 April 2005.
93. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 2005. URL: http://www.bnf.org/bnf
94. Stevenson MD, Brazier JE, Kanis J, Lloyd-Jones M. Cost-effectiveness of current treatments for established female osteoporosis. Osteoporos Int 2000;11:S11.
95. Office for National Statistics Table 3: Mid-2003 population estimates: England and Wales; estimated resident population by single year of age and sex. 2005. URL: http://www.statistics.gov.uk/statbase/expodata/ Spreadsheets/D8556.xls. Accessed 6 May 2005.
96. Kanis JA, Borgstrom F, Zetheraus N, Johnell O, Oden A, Jonsson B. Intervention thresholds for osteoporosis in the UK. Bone 2005;36:22-32.
97. Melton LJ, III, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA. Cost-equivalence of different osteoporotic fractures. Osteoporos Int 2003;14:383-8.
98. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185-94.
99. Meunier PJ, Slosman D, Delmas PD, Sebert JL, Albanese CV, Brandi ML, et al. The strontium salt S-12911: a new candidate for the treatment of osteoporosis [abstract]. Osteoporos Int 1996;6:241.
100. Reginster JY, Spector T, Badurski J, Ortolani S, Martin TJ, Diez-Perez A, et al. Optimizing patient adherence and persistence in strontium ranelate phase 3 program using a short term run-in study. Osteoporos Int 2002;13:S35-6.
101. Reginster JY, Rizzoli R, Balogh A, Badurski J, Spector T, Tulassay Z, et al. Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent vertebral fracture. Osteoporos Int 2004;15:S113.
102. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-41.